Calculate Your Salary Ranking
Home > PhaseBio Pharmaceuticals Salary

PhaseBio Pharmaceuticals Salary
  • 53
  • 52
  • 63

PhaseBio Pharmaceuticals average salary is $-, median salary is $- with a salary range from $- to $-.
PhaseBio Pharmaceuticals salaries are collected from government agencies and companies. Each salary is associated with a real job position. PhaseBio Pharmaceuticals salary statistics is not exclusive and is for reference only. They are presented "as is" and updated regularly.
Low
-
Average
-
Median
-
High
-
Total 0 PhaseBio Pharmaceuticals Salaries. Sorted by Date, page 1
Ranked By:
Job Title Salaries City Year More Info
Calculate how much you could earn

It's FREE. Based on your input and our analysis.    How we do it?

All fields are required for calculation accuracy.

  • We will send you an email to access your personalized report.
  • We won’t share your email address
Recent PhaseBio Pharmaceuticals Salaries (June 30, 2016)
Assistant Professor University of Oklahoma $42,860 Norman, OK, 73019 01/05/2015
General OMRON $65,998 Houston, TX, 77001 09/07/2015

PhaseBio Pharmaceuticals salary is full-time annual starting salary. Intern, contractor and hourly pay scale vary from regular exempt employee. Compensation depends on work experience, job location, bonus, benefits and other factors.

Real Jobs Salary - Salary List
PhaseBio Pharmaceuticals Information
  • PhaseBio Pharmaceuticals, Inc
  • Industry: BioTech/Drugs
  • City: Malvern, PA
  • PhaseBio is a privately held biotechnology company that enables the peptide therapeutic market with innovative recombinant production technologies. The deltaPhase System is particularly beneficial for long peptides over 30 amino acids and proteins. PhaseBio's deltaPhase(TM) System for recombinant peptides provides significant advantages over other peptide production systems. The simple 4-step process increases yields, enableshigher throughput, and most importantly, eliminates chromatography from the purification step. This could reduce the cost of goods for peptide therapeutics up to 10 fold.